key: cord-0804274-8jcz40rl
authors: Bencharattanaphakhi, Rungrot; Rerknimitr, Pawinee
title: COVID-19 vaccine; Sinovac (CoronaVac) induced cutaneous leukocytoclastic vasculitis
date: 2021-10-09
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.10.002
sha: 2ef3e3e36cc0b163fb519defe7df9b855ede1dc7
doc_id: 804274
cord_uid: 8jcz40rl

nan

this virus, including inactivated whole-virus vaccines, namely CoronaVac (Sinovac Life 23 Sciences, Beijing, China). 1 It is used particularly in Asia, the Middle East and South America. 2

Dermatologic reactions such as erythema, swelling and urticaria have been reported. 1 Cutaneous 25 vascular inflammation however has not been reported from Sinovac (CoronaVac). We herein 26 report 2 cases of CoronaVac-induced cutaneous vasculitis. In conclusion, this is the first report of two CoronaVac-induced cutaneous LCV cases. 

Safety, tolerability, and immunogenicity of an 77 inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, 78 placebo-controlled, phase 1/2 clinical trial

Interim recommendations for use of the inactivated COVID-19 80 vaccine, CoronaVac, developed by Sinovac [WWW document

CoronaVac-2021.1 [accessed on 10

Vasculitis as an adverse 84 event following immunization -Systematic literature review

Leukocytoclastic vasculitis flare 86 following the COVID-19 vaccine

Cutaneous reactions 88 reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom?

Fulminant granulomatosis with polyangiitis presenting with diffuse 94 alveolar haemorrhage following COVID-19